USA should resume the application of vaccines against the covid-19 from Johnson & Johnson, as recommended by a group of experts to health authorities on Friday, after a pause motivated by concern about blood clots.
Health authorities in the United States proposed on April 14 to suspend the vaccine in the wake of some serious cases of blood clots among the millions of Americans who received it.
The panel ruled 10 to 4 in favor of recommending lifting the pause, but the head of the Centers for Disease Control and Prevention (CDC), Rochelle Walensky, will make the final decision.
“Janssen’s covid-19 vaccine is recommended for people 18 years of age and older in the US population under the FDA emergency use authorization,” said the group convened by the CDC.
According to data released Friday, of the 3.9 million women who got the Johnson & Johnson injection, 15 developed severe blood clots and three died.
Most of the confirmed cases, 13 of the 15, were under the age of 50. There were no cases among men.
The European drug regulator said on Tuesday that blood clots should be listed as a “very rare” side effect of Johnson & Johnson’s coronavirus vaccine.
The regulator said its safety committee “concluded that a warning about unusual blood clots with low platelets should be added to the product information” for the J&J vaccine.